BUSINESSBLOOMBERG
AstraZeneca Investors See Little Logic in Bristol Tie-Up
AstraZeneca Plc investors expressed disapproval of a proposed $400 billion merger with Bristol-Myers Squibb Co. Bloomberg Intelligence's Sam Fazeli discussed the reaction to the deal.
Mentioned
Related Signal
Adjacent reporting
- AstraZeneca stock sinks on reports of merger talks with Bristol Myers Squibb
- AstraZeneca investors raise concerns over mega-merger talks
- AstraZeneca Is Said to Have Explored Bristol Myers Merger
- AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb
- AstraZeneca reported tie-up talks with Bristol-Myers Squibb are moving stocks. Analysts are puzzled.
- AstraZeneca holds talks with Bristol Myers Squibb over £300bn merger